Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemcabene - NeuroBo Pharmaceuticals

Drug Profile

Gemcabene - NeuroBo Pharmaceuticals

Alternative Names: CI-1027; Gemcabene calcium; PD 0072953; PD 072953

Latest Information Update: 30 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Emory University; NeuroBo Pharmaceuticals; Pfizer
  • Class Antihyperlipidaemics; Antihypertensives; Antirheumatics; Caproates; Hepatoprotectants; Small molecules
  • Mechanism of Action Acetyl-CoA carboxylase inhibitors; Apolipoprotein C-III inhibitors; C-reactive protein inhibitors; CCR2 receptor antagonists; CCR5 receptor antagonists; Lipoprotein A inhibitors; Peroxisome proliferator-activated receptor agonists; Sulfatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypercholesterolaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Hypercholesterolaemia; Hyperlipoproteinaemia; Hypertension; Hypertriglyceridaemia; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Osteoarthritis

Most Recent Events

  • 30 Mar 2020 NeuroBio expects to receive a response from the US FDA regarding removal of the partial clinical hold in the second quarter of 2020
  • 30 Dec 2019 Gemphire Therapeutics has merged into NeuroBo Pharmaceuticals to form NeuroBo Pharmaceuticals
  • 27 Aug 2019 Gemphire Therapeutics and Emory University completes a phase II trial in Non alcoholic fatty liver disease (In children, In adolescents) in USA (NCT03436420)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top